U.S. Office REITs Stock News

If you are trying to figure out whether Apellis Pharmaceuticals is attractively priced today, it helps to start with how the current market value lines up against different ways of estimating fair value. The stock last closed at US$41.01, with returns of 0.1% over 7 days, 0.8% over 30 days, 58.6% year to date and 130.3% over the past year, alongside 3 year and 5 year returns of 53.7% decline and 10.1% decline respectively. This gives a mixed picture for anyone thinking about entry or exit...

Earlier this week, enGene Therapeutics reported interim Phase 2 LEGEND trial results for its bladder cancer gene therapy detalimogene voraplasmid, revealing a 54% complete response rate but weaker 12‑month durability than previously expected, alongside generally manageable side effects and low disease progression. The mixed efficacy profile has triggered analyst downgrades and shareholder-rights investigations, highlighting how a single data update can rapidly reshape perceptions of a...

NiSource (NYSE:NI) announced new and expanded partnerships with Amazon and Alphabet that are expected to support $1.4 billion in customer savings over 15 years. Alongside these partnerships, the company updated its long term adjusted EPS growth outlook to a range of 9% to 10% through 2033. For investors watching utilities, NiSource stands out with a current share price of $47.02 and a 5 year return of 115.2%. The stock has also returned 21.9% over the past year and 83.7% over 3 years,...

This article examines whether Primo Brands, trading at around US$22.24, currently represents value or risk by exploring what the share price might be implying. The stock has returned 9.1% over the last 7 days, 21.3% over the last 30 days and 37.4% year to date, while the 1 year return reflects a 29.8% decline and the 3 and 5 year returns are 69.8% and 48.4% respectively. Recent market interest in Primo Brands appears tied to broader investor attention on beverage companies listed in the US...

Encore Capital Group (NasdaqGS:ECPG) is asking shareholders to approve an amendment to its corporate charter. The change would exculpate company officers from personal liability for monetary damages tied to breaches of the duty of care. The proposal is scheduled for a vote at the upcoming annual shareholder meeting. Encore Capital Group operates in the consumer debt buying and collections space, where regulatory scrutiny, legal risk and reputational considerations tend to be front and...

If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implying about expectations. The stock has returned 5.0% over the last 7 days, 7.2% over 30 days, 25.3% year to date and 16.5% over the past year. This puts recent pricing in clear focus for anyone weighing upside against risk. Recent coverage has centered on Alkermes’ position in the pharmaceuticals and biotech space and how its pipeline...

Wondering whether Privia Health Group at around US$23.99 is offering fair value or a potential opportunity? This article breaks down what the current price may be telling you. The stock has been volatile recently, with a 3.5% decline over the last 7 days, a 7.2% gain over the last 30 days, and year to date returns of 2.3% after a 4.3% loss over the past year. Those mixed returns come against a backdrop of ongoing interest in healthcare services companies focused on physician enablement and...

Wondering whether Verra Mobility stock is starting to look appealing at its current price, especially after a tough run? This article focuses squarely on what that price might really imply about value. The stock last closed at US$14.63 and has returned 0.5% over 30 days, yet year to date it is down 34.5% and the 1 year return is a 39.7% decline, which can change how investors think about both risk and opportunity. Recent coverage has focused on how the stock's weaker 1 year and 3 year...

Akebia Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$53.54 million versus US$57.34 million a year earlier, with net loss of US$9.05 million replacing prior net income of US$6.11 million. A recent proposal to increase authorized capital stock to 525,000,000 shares, including 500,000,000 common shares, adds a potential dilution and financing angle to Akebia’s weaker quarterly performance. Next, we’ll examine how the shift to a quarterly loss alongside...

If you are wondering whether MetLife at around US$78.82 offers fair value or a margin of safety, this article explains what the current price might be indicating. The stock has returned 10.7% over the last 30 days, while the 1-year return is 3.8% and the 3-year return is 67.2%. These figures can influence how investors view both potential upside and risk. Recent coverage has highlighted MetLife's position as a major US insurance company. Investors have been focusing on how interest rate...

If you are wondering whether UGI is attractively priced or just a value trap, starting with the current share price and valuation checks can help frame the picture. UGI closed at US$32.32, with recent returns showing a 10.4% decline over 7 days, 12.7% over 30 days, 14.1% year to date, and 3.6% over 1 year. This is set against a 31.7% gain over 3 years and an 11.3% decline over 5 years. These mixed return figures sit alongside ongoing investor attention on UGI as a regulated utility and...

QuantumScape (NasdaqGS:QS) has started operations at its Eagle Line pilot-scale solid-state battery production facility. The company has recorded its first billings from ecosystem partners, initiating its licensing and royalty revenue stream. These developments represent a shift from pure development work to initial commercialization and monetization of its battery technology. QuantumScape focuses on solid-state lithium-metal batteries aimed at electric vehicles and related applications, a...

For investors wondering if Brady's current share price still offers value or if most of the opportunity is already priced in, this article walks through what the numbers are really saying about the stock. Brady closed at US$79.53, with a 2.8% decline over the last 7 days and a 1.0% decline over 30 days, while still showing returns of 1.1% year to date and 9.9% over the last year. These price moves sit against a backdrop of ongoing investor interest in Commercial Services companies like Brady...

In the first quarter of 2026, Energy Recovery, Inc. reported sales of US$9.71 million, a wider net loss of US$12.25 million, a US$1.66 million goodwill impairment, and announced upcoming CEO retirement alongside the resignation of its CFO. The company also withdrew its 2026 financial guidance amid Middle East uncertainty, even as new product launches and desalination demand supported revenue growth. Next, we’ll examine how the withdrawal of 2026 guidance reshapes Energy Recovery’s investment...

In late April 2026, Phathom Pharmaceuticals reported that its first-quarter net loss narrowed to US$30.37 million from US$94.32 million a year earlier, while maintaining full-year 2026 net revenue guidance of US$320 million to US$345 million and expecting operating profitability, excluding stock-based compensation, to begin in the third quarter of 2026. The company also disclosed a change in how it classifies certain third-party costs starting January 1, 2026, which could make future margins...

Ascendis Pharma (NasdaqGS:ASND) has just posted its Q1 2026 numbers, with revenue of €246.6 million and basic EPS of €10.2, alongside trailing twelve month revenue of €865.8 million and basic EPS of €8.12. Over the past year, revenue has moved from €363.6 million in Q4 2024 to €865.8 million on a trailing basis, while basic EPS has shifted from a trailing loss of €6.53 to positive €8.12. This sets up a quarter where reported profitability and revenue scale give investors a clearer view of how...

If you are wondering whether Rithm Capital at around US$9.79 is a bargain or a value trap, the starting point is understanding what the current price actually reflects. The stock has recent returns of 0.1% over 7 days, 3.1% over 30 days, a 10.8% decline year to date, a 4.7% decline over 1 year, 64.2% over 3 years and 59.1% over 5 years. This gives you a mixed picture of short term weakness against longer term gains. Recent headlines have focused on Rithm Capital's positioning within...

Why TSS (TSSI) is in focus after Q1 2026 earnings and leadership moves TSS (TSSI) is drawing attention after reporting Q1 2026 results that showed lower revenue and net income year over year, alongside new senior hires focused on AI infrastructure and enterprise technology. For the quarter ended March 31, 2026, TSS reported revenue of US$55.35 million compared with US$98.96 million a year earlier, with net income of US$2.28 million versus US$2.98 million in the prior period. Basic and diluted...

Investors may be wondering if Indivior Pharmaceuticals at US$39.60 is still offering value after its strong run, or if most of the upside is already reflected in the price. The stock has returned 7.7% over the last week, 30.0% over the last month, 10.8% year to date and 260.7% over the last year. This naturally raises questions about how the risk reward trade off now looks. Recent news around Indivior Pharmaceuticals has focused on its position in the pharmaceuticals space and how the market...

Avis Budget Group (NasdaqGS:CAR) has entered a new partnership with Silver Airways. Avis and Budget become Silver Airways’ preferred car rental providers for its travelers. The partnership is set to offer exclusive benefits to Silver Airways customers booking car rentals. Avis Budget Group, the parent company of the Avis and Budget car rental brands, is expanding its reach through this new airline partnership with Silver Airways. For readers, a key consideration is how closer integration...

Griffon (NYSE:GFF) is repositioning as a pure-play North American building products company. The company formed a joint venture for AMES North America and exited its UK and Australian operations. Management is pairing this focus with product development efforts and actions on dividends and share buybacks. For you as an investor, this refocus centers Griffon on a single region and core building products activities, rather than a mix of international operations. It follows an industry pattern...

Investors may be wondering whether Permian Resources, at around US$20 a share, still offers value or if most of the opportunity is already priced in. The stock has been volatile recently, with a 7.1% decline over the last week and a 6.1% decline over the last month. Even so, it still sits on a 39.4% return year to date and a 60.7% return over the last year. These moves come against a backdrop of ongoing attention on the company within the US energy sector, as investors weigh its position in...

Wondering if PACCAR at around US$114 is offering fair value or if the market is missing something in the current price. The stock has eased back recently, with a 4.0% decline over the last 7 days and a 3.5% decline over the last 30 days, even though the 1 year return sits at 27.8% and the 5 year return at 117.8%. These moves come as PACCAR continues to attract attention in longer term performance discussions, where investors are weighing up its track record and future expectations. Recent...

Amprius Technologies (NYSE:AMPX) announced a public warrant exchange with institutional holders aimed at reducing potential dilution and reshaping its capital structure. The company reported approximately US$500 million in new purchase orders from U.S. defense customers. Amprius also secured a US$21 million order from a leading Chinese electric mobility firm, pointing to growing commercial adoption across regions. For investors tracking battery suppliers, Amprius Technologies sits at the...